Testing Gemcitabine and Docetaxel Directly in the Bladder for Bladder Cancer
Tests two cancer drugs, given into the bladder, in adults with low grade bladder cancer.
Key facts
- Who runs it
- University of Florida
- Where
- Gainesville, United StatesSee the site
- Trial code
- Registry title
- Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 34 people, planned
- Started
- 5 Nov 2024
- Expected to end
- Aug 2027
- Type of study
- Interventional
- Treatments tested
- Docetaxel
- Gemcitabine
- Record updated
- 11 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with low-grade, intermediate-risk bladder cancer (urothelial carcinoma) and no visible disease on cystoscopy. It tests gemcitabine and docetaxel placed into the bladder.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Low-grade (Ta) intermediate-risk urothelial carcinoma of the bladder: recurrent low-grade Ta, a single low-grade Ta tumour larger than 3 cm (1.2 in), or multifocal low-grade Ta. Up to 10% high-grade component is allowed.
- Earlier treatment
- No prior treatment with intravesical BCG. No live-virus vaccine within 30 days before the first dose.
Main reasons for not taking part
- History of high-grade urothelial carcinoma of the bladder or upper tracts
- Prior BCG treatment in the bladder
- Pure squamous cell carcinoma or adenocarcinoma, or any neuroendocrine carcinoma component
- Anatomic abnormalities that prevent urethral catheter placement, or low bladder capacity
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Adults ≥ 18 years of age
- Low-grade (Ta) Intermediate risk urothelial carcinoma of the bladder (defined as recurrent low-grade Ta, solitary low-grade Ta > 3 cm, multifocal low-grade Ta). Up to 10% high grade component is allowed
- ECOG Performance Status of 0-2
- No evidence of upper tract urothelial carcinoma based on CT, MRI, or retrograde pyelograms
- No urethral involvement based on cystoscopy
- No visible disease based on cystoscopy within 60 days of study enrollment
- Neutrophil counts ≥ 1500 cells/mm3
- Platelet counts >100,000 cells/mm3
- Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen [as determined by the treating physician or approved by the PI] may be included
- Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 6 months after the last dose of study drug to minimize the risk of pregnancy. Prior to study enrollment, subjects of childbearing potential must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy
- Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 3 months following the last dose of study drug
- Written informed consent obtained from the subject and the subject agrees to comply with all the study-related procedures
Who cannot take part
- Prior treatment with intravesical BCG
- Low bladder capacity (determined by the treating Urologist) which prohibits treatment with intravesical therapy
- Subjects of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 6 months after the last dose of study drug
- Administration of a vaccine containing live virus within 30 days prior to the first dose of trial treatment. Note: Most flu vaccines are killed viruses, with the exception of the intra-nasal vainer (Flu-Mist) which is an attenuated live virus and therefore prohibited for 30 days prior to first dose
- Subjects who have a history of high-grade urothelial carcinoma of the bladder or upper tracts
- Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness
- History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician
- Pure squamous cell carcinoma or adenocarcinoma
- Any component of neuroendocrine carcinoma
- Anatomic abnormalities that prohibit urethral catheter placement
- Subjects who are confirmed to be pregnant or breastfeeding
Where in United States
- University of FloridaGainesville, United StatesContact: Karine CharlesTaking people
About the trial
What the trial wants to find out
Bladder cancer is the 8th most common cancer in the UF Health Cancer Center catchment area and the 7th most common cancer presenting to UFHealth. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle invasion and no evidence of disease beyond the bladder. The current use in BCG (Bacillus Calmette-Guerin) refractory disease and the ongoing evaluation in BCG naïve high-risk disease support evaluation of intravesical gemcitabine and docetaxel in decreasing disease recurrence in intermediate risk stage I bladder cancer.
Read full original descriptionShow less
This study will investigate the efficacy and subject compliance with treatment of low grade intermediate risk bladder cancer with intravesical gemcitabine and docetaxel.
The group in the trial
- Docetaxel and GemcitabineTreatment being tested
All subjects will be treated with docetaxel and gemcitabine in 2 phases (induction and maintenance) following transurethral resection. Docetaxel and gemcitabine will be given weekly for six weeks during induction and will then be given every 30 days until up to 12 months after the start of induction therapy during maintenance.
Treatment: Docetaxel and Gemcitabine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
- Plain-language title
- Testing Gemcitabine and Docetaxel Directly in the Bladder for Bladder CancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 March 2026